PubMed · 16162083
Rizatriptan in migraine.
Abstract
The prevalence of migraine is high, affecting a significant proportion of the adult population during their most productive years of life and promoting impairment of their normal daily activities. Although guidelines for the acute treatment of migraine are available, outcome parameters are sometimes still below the expectations of both patients and physicians. Triptans represented an advance in clinical practice and have become the most well-studied class of medication for migraine. These agents present class I evidence for efficacy. However, they differ with regard to several of their clinical parameters, including onset of relief and consistency of response. Rizatriptan is a selective agonist of the 5-hydroxytryptophan(1B/1D )receptors, with proven superiority over placebo, ergotamine and selected oral triptans, demonstrating a good profile of safety and tolerability.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Abouch Valenty Krymchantowski, Marcelo Eduardo Bigal. 2005. Rizatriptan in migraine.. https://doi.org/10.1586/14737175.5.5.597
Cite the original work for its findings. Save a collection to share your selection of sources.